Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma

Jun Itoh, Koji Mitsuzuka, Shingo Kimura, Takaki Tanaka, Taku Yamamuro, Shinichi Yamashita, Shigeyuki Yamada, Hideo Saito, Yasuhiro Kaiho, Yoichi Arai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Abstract:: The present case report describes two cases of unresectable advanced primary urethral carcinoma. Case 1 was a 61-year-old man with squamous cell carcinoma of the urethra that directly invaded into the perineal skin. Case 2 was a 64-year-old woman with adenocarcinoma, and solitary lung and lymph node metastases. Both patients received docetaxel/cisplatin/5-fluorouracil chemotherapy with concurrent radiation. The docetaxel/cisplatin/5-fluorouracil chemotherapy regimen consisted of docetaxel (75mg/m2) on day 2, cisplatin (100mg/m2) on day 2 and 5-fluorouracil (1000mg/m2) on days 1 to 5 and was repeated every 4 weeks. Complete response was achieved after two cycles of chemotherapy combined with radiation in case 1. In case 2, complete response was achieved locally after six cycles of chemotherapy combined with radiation, but the solitary lung lesion remained viable. We experienced two cases with advanced urethral carcinoma for whom docetaxel/cisplatin/5-fluorouracil chemotherapy chemotherapy with radiation was effective.

Original languageEnglish
Pages (from-to)422-424
Number of pages3
JournalInternational Journal of Urology
Volume21
Issue number4
DOIs
Publication statusPublished - 2014 Apr

Keywords

  • Adenocarcinoma
  • Chemotherapy
  • Radiation therapy
  • Squamous cell carcinoma
  • Urethral cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma'. Together they form a unique fingerprint.

  • Cite this